Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan

1

The study evaluated 257 patients with hematological disorders who received Tixagevimab-cilgavimab for COVID-19 prevention in Japan.
2

The incidence of breakthrough COVID-19 in this cohort was 7.5%, with 18 patients contracting the virus after Tix/Cil administration.
3

Most patients experienced mild to moderate COVID-19, with no reported deaths, indicating Tix/Cil's efficacy in preventing severe disease.
4

The median time from Tix/Cil administration to COVID-19 onset was 25 days, with some patients developing the virus within 14 days.
5

This study provides real-world data on breakthrough COVID-19 incidence in immunocompromised patients, highlighting the need for ongoing monitoring.

Bone Marrow Transplantation

by Mizuki Haraguchi, Hisashi Yamamoto, Otoya Watanabe, Takashi Sakoh, Keiko Ishida, Sho Ogura, Masayo Katoh-Morishima, Yuki Taya, Aya Nishida, Daisuke Kaji, Shinsuke Takagi, Go Yamamoto, Naoyuki Uchida, Hideki Araoka
June 17, 2023

1